Evidence map›Paper›PMID 25100291›Full record

ArticleMucosal immunology2015

Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women.

C R Sacha, N Vandergrift, T L Jeffries, E McGuire, G G Fouda, B Liebl, D J Marshall, T C Gurley, L Stiegel, J F Whitesides and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Mucosal immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

C R SachaHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
N VandergriftHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
T L JeffriesHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
E McGuireHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
G G FoudaHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
B LieblHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
D J MarshallHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
T C GurleyHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
L StiegelHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
J F WhitesidesHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
J FriedmanHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
A BadiaboHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
A FoulgerHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
N L YatesHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
G D TomarasHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
T B KeplerDepartment of Microbiology and Department of Mathematics & Statistics, Boston University School of Medicine, Boston, Massachusetts, USA.
H X LiaoHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
B F HaynesHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
M A MoodyHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
S R PermarHuman Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Duke Medical Center · USBoston University · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAHN, BEATRICE H · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Transmission-blocking potential of novel HIV Env-specific mucosal antibodiesR01AI106380 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2013 to 2017
$3.4M
SIV-specific Immunity in breast milk during infection and after vaccinationK08AI087992 · NIAID · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2009 to 2013
$568k
Howard Hughes Medical InstituteNIAID NIH HHS 5P30 AI064518NIAID NIH HHS K08 AI087992NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI106380NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1-AI100645-01
6 · The paper itself

Abstract

A successful HIV-1 vaccine must elicit immune responses that impede mucosal virus transmission, though functional roles of protective HIV-1 Envelope (Env)-specific mucosal antibodies remain unclear. Colostrum is a rich source of readily accessible mucosal B cells that may help define the mucosal antibody response contributing to prevention of postnatal HIV-1 transmission. To examine the HIV-1 Env-specific colostrum B-cell repertoire, single B cells were isolated from 17 chronically HIV-infected, lactating women, producing 51 blood and 39 colostrum HIV-1 Env-specific B-cell antibodies. All HIV-1 Env-specific colostrum-derived antibodies were immunoglobulin (Ig)G1 isotype and had mean heavy chain complementarity-determining region 3 (CDR3) lengths and mutation frequencies similar to those isolated from blood. However, variable heavy chain (VH) gene subfamily 1(∼)69 usage was higher among colostrum than blood HIV-1 Env-reactive antibodies (49% vs. 20%, P=0.006, Fisher's exact test). Additionally, more HIV-1 Env-specific colostrum antibodies were gp120 specific than those isolated from blood (44% vs. 16%, P=0.005, Fisher's exact test). One cross-compartment HIV-1 Env-specific clonal B-cell lineage was identified. These unique characteristics of colostrum B-cell antibodies suggest selective homing of HIV-1-specific IgG1-secreting memory B cells to the mammary gland and have implications for targeting mucosal B-cell populations by vaccination.

Indexed as

LactationAntibody FormationBlack or African AmericanB-LymphocytesCD4 Lymphocyte CountClonal EvolutionColostrumComplementarity Determining RegionsEpitopes, B-LymphocyteFemaleHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41HIV InfectionsHumansComplementarity Determining RegionsEpitopes, B-LymphocyteHIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Immunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Variable Region

Identifiers

PMID25100291
PMCPMC4320043
OpenAlexW2054891028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.